Literature DB >> 416163

Protection against group B meningococcal disease. II. Infection and resulting immunity in a guinea pig model.

C E Frasch, J D Robbins.   

Abstract

A guinea pig subcutaneous chamber model was used to evaluate the specificity of the immune response resulting from Neisseria meningitidis infection. Small numbers of meningococci easily infected the chambers. The infections persisted for 6-8 days with relatively high levels of organisms (10(5)-10(6)/milliliter) in the chambers, and were then rapidly eliminated and no organisms could be cultured beyond day 14. Clearance of infection correlated with appearance of circulating antibody. Antibody against both the protein serotype antigen and the capsular polysaccharide were induced as a result of meningococcal infection. The group-specific polysaccharide response peaked 2-3 wk after the animals were inoculated, while the type-specific protein response peaked at 5-6 wk. The animals were quite resistant to reinfection with either the homologous serogroup or serotype.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 416163      PMCID: PMC2184191          DOI: 10.1084/jem.147.3.619

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

1.  Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method.

Authors:  C E Frasch; S S Chapman
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

2.  Transmission of immunity to Neisseria gonorrhoeae from vaccinated hens to embryos.

Authors:  B B Diena; G Lavergne; A Ryan; F Ashton; R Wallace
Journal:  Immunol Commun       Date:  1976

3.  Recurrent bacterial meningitis: immunologic observations.

Authors:  J D Conger; E A Edwards; W J Jacoby
Journal:  Mil Med       Date:  1971-03       Impact factor: 1.437

4.  Serologic studies of meningococcal infection and polysaccharide vaccination.

Authors:  M S Artenstein; B L Brandt; E C Tramont; W C Branche; H D Fleet; R L Cohen
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

5.  Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis.

Authors:  D Lim; A Gewurz; T F Lint; M Ghaze; B Sepheri; H Gewurz
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

6.  Comparative physical and immunological aspects of the chimpanzee and guinea-pig subcutaneous chamber models of Neisseria gonorrhoeae infection.

Authors:  R J Arko; K H Wong
Journal:  Br J Vener Dis       Date:  1977-04

7.  Human antibody response to three meningococcal outer membrane antigens: comparison by specific hemagglutination assays.

Authors:  W D Zollinger; C L Pennington; M S Artenstein
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

8.  Morphological, biological and antigenic properties of Neisseria gonorrhoeae adapted to growth in guinea-pig subcutaneous chambers.

Authors:  C W Penn; D Sen; D R Veale; N J Parsons; H Smith
Journal:  J Gen Microbiol       Date:  1976-11

9.  Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.

Authors:  C E Frasch; L Parkes; R M McNelis; E C Gotschlich
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

10.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Animal models for pathogenic Neisseria species.

Authors:  R J Arko
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

Review 2.  The meningococcus and mechanisms of pathogenicity.

Authors:  I W DeVoe
Journal:  Microbiol Rev       Date:  1982-06

3.  Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.

Authors:  M S Peppler; C E Frasch
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

4.  Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.

Authors:  D E Craven; C E Frasch
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

5.  Experimental meningococcal infection in mice: a model for mucosal invasion.

Authors:  I E Salit; L Tomalty
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

6.  Enzyme-linked immunosorbent assay compared with immunoprecipitation for serotyping Neisseria meningitidis and its use in demonstrating serotype polymorphism.

Authors:  E B Mackie; L A White; K N Brown; L E Bryan
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

7.  Serum and salivary antibody responses in rats orally immunized with Streptococcus mutans carbohydrate protein conjugate associated with liposomes.

Authors:  D Wachsmann; J P Klein; M Scholler; J Ogier; F Ackermans; R M Frank
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide.

Authors:  C Moreno; M R Lifely; J Esdaile
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.